What analysts say:
- Buy, sell, or hold?: Analysts strongly back Neogen, with four of six rating it a buy and the remainder rating it a hold. Analysts like Neogen better than competitor Meridian Bioscience overall. Analysts haven't adjusted their rating of Neogen for the past three months.
- Revenue forecasts: On average, analysts predict $46 million in revenue this quarter. That would represent a rise of 8.8% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.23 per share. Estimates range from $0.20 to $0.25.
What our community says:
CAPS All-Stars are solidly behind the stock, with 100% granting it an outperform rating. The community at large agrees with the All-Stars, with 97% assigning it a rating of outperform. Even with a robust four out of five stars, Neogen's CAPS rating falls a little short of the community's upbeat outlook.
Neogen's profit has risen year-over-year by an average of 11.2% over the past five quarters. Revenue has now gone up for three straight quarters.
For all our Neogen-specific analysis, including earnings and beyond, add Neogen to My Watchlist.
The Motley Fool has a disclosure policy.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.